middle.news
Noxopharm’s SOF-16 Shows Strong Anti-Inflammatory Effects in Lupus and Arthritis Samples
9:32am on Friday 1st of May, 2026 AEST
•
Biotechnology
Read Story
Noxopharm’s SOF-16 Shows Strong Anti-Inflammatory Effects in Lupus and Arthritis Samples
9:32am on Friday 1st of May, 2026 AEST
Key Points
SOF-16 reduces inflammation in lupus patient blood samples
Joint fluid from rheumatoid arthritis patients shows marked response to SOF-16
Data supports expansion of Sofra platform into systemic autoimmune diseases
Research led by Professor Michael Gantier with international collaborators
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE